3Gibbs BF,Schmutzle W,Vollrath ID,et a1.Ambroxol inhibitsths release Of histamine,leukotrienes and cytokines from human leukocytes and mast cells[J].Inflammation Research,1999,48:86-93.
二级参考文献5
1罗慰慈，中国新药杂志，1992年，1卷，4期，42页
2B. F. Gibbs,W. Schmutzler,I. B. Vollrath,P. Brosthardt,U. Braam,H. H. Wolff,G. Zwadlo-Klarwasser. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells[J] 1999,Inflammation Research(2):86～93
3A. Gillissen,A. Bartling,S. Schoen,G. Schultze-Werninghaus. Antioxidant Function of Ambroxol in Mononuclear and Polymorphonuclear Cells in Vitro[J] 1997,Lung(4):235～242
4R. R. Wauer,G. Schmalisch,B. B?hme,J. Arand,D. Lehmann. Randomized double blind trial of Ambroxol for the treatment of respiratory distress syndrome[J] 1992,European Journal of Pediatrics(5):357～363
5Maria Giulia Marini. Prevention by ambroxol of bronchopulmonary complications after upper abdominal surgery: Double-blind italian multicenter clinical study versus placebo[J] 1991,Lung(1):69～76
5Aihara M,Dobashi K,Akiyama M,et al.Effects of nacetylcgsteine and ambroxol on IL-2 and IL-10 in human alveolar macrophagse[J].Respiratio,2000,67(6):662-671.
6Tashkin DP,Cooper CB.The role of long-acting bronchodilators in the management of stable COPD[J].Chest,2004,125(1):249-259.
7Husereau D,Shukla V,Boucher M.Long acting beta 2 agonists for stablechronic obstructive pulmonary disease with poor reversibility:a systematic review of randomised controlled trials[J].BMC Pulm Med,2004,4:7-17.
